ArticleFrontiers in pharmacology2026
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the renin-angiotensin system and inflammatory pathways.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Essential tremor (ET) is a widespread neurological disorder with mild cerebellar degeneration that affects motor coordination, causing involuntary, rhythmic tremors during action. Excessive brain renin-angiotensin system activation favors pro-inflammatory milieu that is associated with neurodegenerative diseases. Objective: The present study aimed to investigate the neuroprotective effects of Telmisartan (TELMI), an angiotensin receptor blocker, in a harmaline-induced model of essential tremor. Methods: Male rats were assigned to three groups: control, harmaline (30 mg/kg; i. p.) and a treatment group receiving TELMI (3 mg/kg/day; p. o.) administered 5 days before harmaline induction. Results: TELMI reduced tremor severity and enhanced performance in the rotarod, wire grip strength, footprint test, open field test, and gait kinematics. Cerebellar molecular analysis revealed that TELMI significantly increased MAS receptor expression and angiotensin 1-7 levels, while concurrently downregulating angiotensin II type 1 and 2 receptors. The levels of ACE1/ACE2 confirmed the favoring of the beneficial RAS arm. This modulation notably inhibited the activation of p38 MAPK and reduced pro-inflammatory cytokines, including TNF-alpha, IL-1-beta, IL-6, and chemokine receptor type 4. Neurotransmitter analysis showed restoration of the excitatory/inhibitory balance between GABA and glutamate levels. Immunohistochemical analysis of Bergmann cells in the cerebellum demonstrated marked reductions in the proliferative marker; Ki67, and markers of glial and progenitor cell activity; S100β and SOX2 expression, respectively, concurrently with, the suppression of the neural stem cell marker; nestin. Conclusion: These findings suggest that TELMI protects against cerebellar neurodegeneration in essential tremor by exerting anti-inflammatory, anti-excitotoxic, and receptor-modulatory effects through the Ang 1-7/MAS receptor and p38 MAPK signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.